April 2019

CURRICULUM VITAE

Nancy M. P. King, JD

Office: Professor
Department of Social Sciences and Health Policy
Division of Public Health Sciences
Wake Forest University School of Medicine
525@Vine, Room #3132
Medical Center Boulevard
Winston-Salem, NC 27157
Telephone: (336) 716-4289
E-Mail: nmpking@wakehealth.edu

EDUCATION:

College: BA magna cum laude, St. John's College, Annapolis, MD, May, 1975.

Law School: JD with honors, University of North Carolina School of Law, Chapel Hill, NC, May 1980. Order of the Coif. John Motley Morehead Fellow in Law. Staff *North Carolina Law Review*.

PROFESSIONAL LICENSURE:

Member, Maryland Bar, October 1980-Present

Member, North Carolina Bar, August 1983-Present

EMPLOYMENT:

January 2007-present: Professor, Department of Social Sciences and Health Policy, Wake Forest School of Medicine

2014-present: Adjunct Professor, Department of Social Medicine, UNC School of Medicine

2009-present: Co-Director, WFU Center for Bioethics, Health, and Society. Responsibilities include administration, development, conference and program planning, proposal review and support, and university, regional, and statewide bioethics collaborations.

2008-present: Co-Director, WFU Graduate Program in Bioethics. Responsibilities include extensive administration, development, and teaching.

Director, Program in Bioethics, Health, and Society. Cross-appointments: Department of Internal Medicine (2007-2012); Institute for Regenerative Medicine. Co-Primary appointment: Translational Science Institute. Adjunct appointment: School of Law.
Responsibilities include directing and teaching research ethics course in Clinical & Population Translational Science Master's Program; clinical and research ethics education sessions for medical students, residents, fellows, and faculty; and research ethics consultation.

July 1999-January 2007: Professor, Department of Social Medicine, UNC-Chapel Hill. Responsibilities included teaching medical students in the first and second years in seminar and lecture formats. Service included both IRB and Hospital Ethics Committee membership.
July 2001-June 2005: Vice-Chair, Department of Social Medicine, UNC-Chapel Hill.

July 1993-June 1999: Associate Professor, Department of Social Medicine, UNC-Chapel Hill. Acting Chair, July 1-December 31, 1995.
Adjunct Associate Professor, UNC School of Law, 1993-1996.

July 1987-June 1993: Assistant Professor, Department of Social Medicine, UNC-Chapel Hill.
August 1983-July 1987: Adjunct Instructor, Department of Social and Administrative Medicine, UNC-Chapel Hill.

January 1982-September 1983: Research Attorney to Professor Clark C. Havighurst, Program on Legal Issues in Health Care, Duke University Law School.

November 1980-December 1981: Attorney, Health Care Financing and Human Development Services Division, Office of the General Council, OS, DHHS. GS-11 Civil Service, recommended for promotion.

May-October 1980: Legal consultant, Kennedy Institute of Ethics, Center for Bioethics, Georgetown University, Washington, D.C.

PROFESSIONAL APPOINTMENTS AND ACTIVITIES:

Member, Data and Safety Monitoring Board for REHAB-PH Study, NHLBI, beginning 2019.

Member, Editorial Board, *Ethics & Human Research*, beginning 2018.

Member, Data and Safety Monitoring Board for PHANTOM Study, NHLBI, beginning 2017.

Member, Secretary's Advisory Committee for Human Research Protections, OS/DHHS, 4-year term beginning Oct. 21, 2015. Member, SACHRP Subpart A Subcommittee, same term.

Member, Data and Safety Monitoring Board, AIDS Malignancy Consortium, NCI, NIH, term beginning 2015.

Member, Editorial Board, *Current Stem Cell Reports*, beginning 2014.

Member, Ethics Committee, American Society of Gene and Cell Therapies, 2012-2016.

Member, Editorial Advisory Board, *Trials*, beginning 2011.

Member, Publications and Presentations Committee, Women's Health Initiative, beginning 2010.

Member, Core Conference Planning Committee, PRIM&R, 2009-2010.

Member, Data and Safety Monitoring Board for BRIDGE Study, NHLBI, 2009-2014.

Member, Advisory Board, Center for Applied and Professional Ethics, UNC-Charlotte, beginning 2007.

Member, Vaccine & Prevention Data and Safety Monitoring Board, NIAID, NIH, 2007-2011.

Member, Clinical Trial Design Task Force, NIH, beginning 2007.

Member, IPF Data and Safety Monitoring Board, NHLBI, NIH, 2007-2008.

Member, AAMC Task Force on Industry Support for Medical Education, 2007-2008.

Advisory Group Member, National Resource Center on Psychiatric Advance Directives, beginning 2006.

Member, Data and Safety Monitoring Board for DB289, Immtech Pharmaceuticals, Inc., 2006-2008.

Member, International Board and Ethical Review Board, Clinigene Network of Excellence for Gene Transfer Research, 2006-2011. Vice-Chair, Ethical Review Board, 2009-2011.

Member, Ethics and Policy Working Group, North Carolina Genomics Task Force, 2004-2005.

Member, Gene Transfer Data Safety Monitoring Board, National Heart, Lung and Blood Institute, NIH, 2004-2006.

Member, Blue Ribbon Committee for Surgical and Invasive Clinical Trials, Veterans Administration, 2003.

Member,Editorial Board, *Journal of Law, Medicine and Ethics*, 2003-present.

Co-Chair, Recombinant DNA Advisory Committee Gene Transfer Clinical Trial Design Working Group, 2003-2006.

Co-Chair, Recombinant DNA Advisory Committee Informed Consent Working Group, NIH, 2002-2003.

Ad Hoc Consultant, Office for Human Research Protections, DHHS, 2000-present.

Member, Recombinant DNA Advisory Committee, NIH, 1998-2002.

Legal Consultant, Committee on Bioethics, American Academy of Pediatrics, 1995-1998.

Member, DNR Task Force, North Carolina Medical Society, 1995-97. Drafted materials for revised portable statewide Do-Not-Resuscitate order.

Member, Committee on Evaluation of 1950s Air Force Human Health Testing in Alaska Using Radioactive I^{131} (NAS 1994).

Editorial Board Member, *HEC Forum*, 1991-2005.

Manuscript Reviewer, various journals, including *IRB: Ethics and Human Subjects Research; Hastings Center Report; Journal of Law, Medicine, and Ethics; Journal of Medicine and Philosophy*: 1990-present.

Member, Committee for the Protection of Human Subjects, Research Triangle Institute, 1990-1996.

Member, Medicine and Society Program Advisory Committee, North Carolina Humanities Council, 1984-1988.

INSTITUTIONAL SERVICE:

WFU/WFSM/WFBMC:

Member, Industry Relations Policy Committee, WFUBMC, 2008-2010.

Member, Proposal Review Committee, Ethics, Leadership, and Civic Responsibility Fund, WFU, 2008-2010.

Founding Member, Institutional DSMB, 2008-present.

At-Large Member, Translational Science Institute Executive Committee, and Co-Chair, TSI Steering Committee, 2007-2008. Member, Steering Committee, 2008-2010.

Director, Program in Bioethics, Health, and Society, WFBMC TSI, 2007-2010.

Member, Scientific Integrity and Research Ethics (SIRE) Committee, WFSM, 2007-2012. SIRE Chair, July 2008-June 2012.

Creator/Director, WFBMC/WFU Research Ethics Consultation Program, 2009-present.

Member, Clinical Ethics Committee, and Policy and Organizational Ethics Subcommittees, WFBMC, 2007-present.

Member, Institutional Biosafety Committee, term beginning 2016.

Member, Cancer Center DSMB, term beginning 2018.

UNC:

Member, Ad Hoc Committee on Tissue Banks and DNA Repositories, 2006.

Member, Faculty Advisory Council, Parr Ethics Center, 2005-2006.

Member, UNC School of Medicine Human Gene Transfer Research Review Committee, 2003-2006.

Member, Ad Hoc Faculty Advisory Committee on Stem Cell Research, 2002-2006.

Member, Human Research Accreditation Task Force, 2002-2005.

Founding Member, UNC School of Medicine Standing Data Safety Monitoring Board, 2001-2006.

Co-Director, Program in Bioethics, Mental Health Clinical Research Center, 1997-1998.

Co-Chair, Ethics Committee, University of North Carolina Hospitals, 1997-2003. (Member 1993- 2006).

Director, UNC Hospitals Ethics Education Service, 1997-2006.

Member, Biomedical IRB, UNC Hospitals-School of Medicine, 1996-2006.

Faculty Advisor, *Iris: The UNC Journal of Medicine, Literature and Visual Art*, 1996 - 2001.

Member, Curriculum Evaluation Committee, 1996-1999.

Member, UNC Hospitals Ethics Consultation Service, 1995-2006.

Member, Fetal Tissue Research Task Force, UNC School of Medicine, 1993-1994.

Interim Member, Infant Care Review Committee, University of North Carolina Hospitals, June-December 1985; Member, 1990-1998.

PROFESSIONAL MEMBERSHIPS AND SERVICE:

North Carolina Society of Health Care Attorneys

American Health Lawyers' Association

American Society of Bioethics and Humanities

Health Law Professors Section, American Society of Law, Medicine, and Ethics

European Society for the Philosophy of Medicine and Healthcare

Association of Bioethics Program Directors 2005-2010

HONORS AND AWARDS:

Fellow of the Hastings Center, elected June 2002.

UNC School of Medicine Teaching Excellence Award, 2001, 2005.

UNC Kenan Leave award, Fall 1999.

UNC Philip and Ruth Hettleman Award for Artistic and Scholarly Achievement of Young Faculty, 1992.

PROFESSIONAL INTERESTS:

My area of special concentration is the study of roles, relationships, and responsibilities in health care decisions, in both medical treatment and biomedical research, at the level of individuals, institutions, government, and society. Answering three essential questions about a health care decision -- who should make it, how should it be made, and how should it be evaluated (is it right)? -- produces an understanding, based on bioethics and law, of how authority and responsibility in health care decisionmaking are and should be delineated, and facilitates analysis and improvement of policy and practice in clinical and research settings. I have worked extensively on issues related to informed consent in health care and research; medical decisions at the beginning and end of life; the development and use of experimental technologies; preclinical and animal research; international and cross-cultural questions in human subjects research; benefit and uncertainty in human subjects research; ethical issues in large-scale genetic research and biobanking, gene transfer research, and regenerative medicine; and connections between science, ethics, design, and policy in biotechnology research. I have served on hospital ethics committees, IRBs, and DSMBs, and have taught research ethics in national and international settings.

CURRENT GRANT SUPPORT:

1U01TR001792-01 (Bailey, PI) 09/15/16-6/30/21 2.4 calendar months
NIH/NCATS $800,000 total annual direct
Early Check: A Collaborative Innovation to Facilitate Pre-Symptomatic Clinical Trials in Newborns
My role is MPI of WFBMC CTSI subcontract in this multiple PI model, addressing research ethics, human subjects protections, implementation, and research-to-treatment transitions.

PAST GRANT HISTORY:

2P50HG004488-06 (Henderson, PI) 04/01/13 - 03/31/18 1.4 calendar months
NIH/NHGRI $750,000 annual direct
Center for Genomics and Society
My role as Co-I was Director of Trans-CEER Coordination for all Centers of Excellence in ELSI Research.

1R25HD068722-01A1 (Estroff, PI) 7/1/2012 - 3/31/2016; no-cost extension ending 3/31/2017
5R25HD068722-02 (PI of WFSM subcontract)
NIH/NICHD $97,214 annual direct 2 calendar months
Innovating and Enhancing Behavioral and Social Science Medical Student Curricula
My role was PI of WFSM subcontract addressing innovations in WFSM MS1&2 curriculum.

R21 NR013272 (Nageswaran, PI) 05/21/2013 – 05/20/2015 1.2 calendar mos (Co-I)
NIH/NINR $275,000
Healthcare Providers' Roles in Decision Making in Pediatric Palliative Care
Using qualitative methods, this project identified gaps in decision making processes about life-sustaining treatments for children with complex chronic conditions.

Co-Investigator, RC2 CA148463 (Xu, J) 09/09 – 09/11 NIH Clinical validity and utility of genomic targeted chemoprevention of PCa.

Co-Investigator, UO1 DK 062418 (Rich) 09/15/02 – 08/31/10 NIDDK Type 1 Diabetes Genetics Consortium. Served on ELSI committee 1/2007-9/2010.

Co-Investigator, Center for Genomics and Society, one of several Centers of Excellence in ELSI Research. Gail E. Henderson, PI. 10/2007-7/31/2009; consultant, 8/1/2009-3/31/2013.

Co-Principal Investigator (with colleague Gail E. Henderson), Renewal of "Social Construction of Benefit in Gene Transfer Research", also with colleagues Arlene M. Davis, Daniel K. Nelson, and Barbra B. Rothschild. R01 HG 02087, ELSI Program, National Human Genome Research Institute, NIH, 1/01/04-12/31/07, Grant Overall Total $873,470.

"The Disputed Genome: A Community Conversation". Genetics Education Contract Award. Co-investigator, Barbra Rothschild, PI. National Human Genome Research Institute, NIH, 12/05-10-06, Contract Total $100,000.

"ELSI Scale-Up: Large Sample Gene Discovery and Disclosure" Center of Excellence in ELSI Research Planning Grant. Co-Investigator; Don Bailey, PI. 1P20HG03387-01, ELSI Program, National Human Genetics Research Institute, NIH, 7/1/04-6/30/06, Grant Overall Total $438,000.

Co-Principal Investigator (with colleague Gail E. Henderson), "The Social Construction of Benefit in Gene Transfer Research," also with colleagues Larry R. Churchill, Arlene M. Davis, and Daniel K.

Nelson. 1 RO1 HG 02087-01, ELSI Program, National Human Genome Research Institute, NIH, 10/1/99-7/31/03, Grant Overall Total $1,391,392.

Co-Principal Investigator, "Research, Treatment, and Informed Consent in Gene Therapy: An Historical, Ethical, and Legal Analysis and Reevaluation of Policy." With colleagues Larry R. Churchill, Keith A. Wailoo, and Myra L. Collins. Received $100,000 Shannon Award from NIH National Center for Human Genome Research July 1995-June 1997; received full funding from ELSI Program of NIH NCHGR August 1996-July 1998 ($513,132).

Project Director, Public performance/discussion programs, "North Carolina Medicine and Society Readers' Repertory Theater," 1990-91 and 1991-92. Funds from the N. C. Humanities Council under a 2-year major grant from the National Endowment for the Humanities, involving UNC, Duke and ECU medical students traveling to communities around the state for performance and discussion of literature raising medical ethics questions.

Project Director, Public Performance/Discussion Programs, "Staged Readings in Medicine and Society," fall 1988, spring 1989, spring 1990. Grants from the North Carolina Humanities Council to involve medical students in addressing medical ethics questions through the performance and discussion of literature.

Project Director, Symposium Program, "The Physician as Captain of the Ship: A Critical Reappraisal," May 15-17, 1986, Chapel Hill, NC. Coordinated program of invited speakers with interdisciplinary focus on medicine in society. Funding from the Medicine and Society Program, a special project of the North Carolina Humanities Council (a state agency of NEH) and the Duke Endowment; Burroughs Wellcome Corporation; and the American Medical Association Education and Research Foundation.

BIBLIOGRAPHY:

Monographs and textbooks:

1. King NMP and Hyde MJ (eds), *Bioethics, Public Moral Argument, and Social Responsibility*, Routledge, 2012. [Reviewed favorably, JAMA 2012;308:2629-30.]

2. King, N. M. P., Strauss, R. P., Churchill, L. R., Estroff, S. E., Henderson, G. E., and Oberlander, J. (eds.): *The Social Medicine Reader (2nd ed.), volume 1: Patients, Doctors, and Illness*. Duke University Press, 2005.

3. Henderson, G. E., Estroff, S. E., Churchill, L. R., King, N. M. P., Oberlander, J., and Strauss, R. P. (eds.): *The Social Medicine Reader (2nd ed.), volume 2:Social and Cultural Contributions to Health, Difference, and Inequality.* Duke University Press, 2005.

4. Oberlander, J. Churchill, L. R., Estroff, S. E., Henderson, G. E., King, N. M. P. , and Strauss, R. P. (eds.): *The Social Medicine Reader (2nd ed.,) volume 3: Health Policy, Markets, and Medicine.* Duke University Press, 2005.

5. King, N.M.P., Henderson, G., and Stein, J. (eds.): *Beyond Regulations: Ethics in Human Subjects Research*, UNC Press, 1999.

6. Henderson, G., Churchill, L.R., Estroff, S.E., King, N.M.P., and Strauss, R. (eds.): *The Social Medicine Reader*, Duke University Press, 1997.

7. King, N. M. P.: *Making Sense of Advance Directives*, (revised edition), Georgetown University Press, 1996.

8. Committee on Evaluating 1950s Air Force Human Health Testing in Alaska Using Radioactive Iodine^{131} [C. Pierce, D Baines, I Chopra, N. King, K Mossman, C. Elfrig, L. Setlow, T. Greenleaf, M. Stoto and J. Zimbrick], *The Arctic Aeromedical Laboratory's Thyroid Function Study: A Radiological Risk and Ethical Analysis*, National Academy Press, 1996.

9. King, N. M. P.: *Making Sense of Advance Directives*, Kluwer Academic Publishers, 1991.

10. King, N. M. P., Churchill, L. R., and Cross, A. W. (eds.): *The Physician as Captain of the Ship: A Critical Reappraisal*, D. Reidel Publishing, 1988

11. Faden, R., and Beauchamp, T., with King, N. M. P.: *A History and Theory of Informed Consent*, Oxford University Press, New York, 1986.

Chapters in books:

1. King, N. M. P., "Early-Stage Research: Issues in Design and Ethics." In *Regenerative Medicine Ethics: Governing Research and Knowledge Practices*, Hogle, L., ed. Springer-Verlag, 2014.

2. King, N. M. P., "Ethics in Regenerative Medicine and Transplantation." In *Regenerative Medicine Technologies as Applied to Organ Transplantation*. Orlando, G., ed. Elsevier, 2013.

3. King, N. M. P., and Iltis, A. S., "Privacy and Confidentiality in Research." In *Encyclopedia of Bioethics*, 4th ed., Jennings, B., ed., MacMillan Reference USA, 2014, pp 2503-2513.

4. Keys T., King, N. M. P., and Atala, A., "Faith in Science: Professional and Public Discourse on Regenerative Medicine." In *The Language of Our Biotechnological Future*. Hyde, M. J., and Herrick, J., eds. Baylor University Press 2013, pp. 11-39.

5. King, N. M. P. and Moskop, J.C., "Advance Care Planning and End-of-Life Decision Making Guidance for Healthcare Ethics Committees*"* ch 12 in *Guidance for Healthcare Ethics Committees*, Hester, D.M., Schonfeld, T (eds), Cambridge University Press 2012, pp. 80-87.

6. Hall, M.A. and King, N.M.P. "Legal Methods" in Methods in Medical Ethics, 2nd ed., Sugarman, J., and Sulmasy, D.P (eds), Georgetown University Press, 2010.

7. King, N. M. P., "Ethical Issues in Lifestyle Change and Adherence," ch. 38 in the *Handbook of Health Behavior Change*, 3rd ed., Shumaker S. A, Ockene, J. K., Riekert, K. A. (eds), Springer, 2009, pp. 757-770.

8. Sugarman, J., Campbell, C., Citron, P., Foote, S., and King, N. M. P. "Altering Nature: Medical Devices Policy and the Humanities: Examining Implantable Cardiac Devices," in *Altering Nature*, Volume Two: *Religion, Biotechnology, and Public Policy* (Lustig, B. A, Brody, B. A., McKenny, G. P., eds), Springer, 2008, pp. 259-284.

9. King, N. M. P., and Churchill, L. R.: Clinical Research and the Physician-Patient Relationship: The Dual Roles of Physician and Researcher. In *The Cambridge Textbook of Bioethics*, Singer, P. and Viens, A. M. (eds). Cambridge University Press, 2008, pp. 214-221.

10. King, N. M. P., and Churchill, L. R.: Assessing and Comparing Potential Benefits and Risks of Harm. In *Oxford Textbook of Clinical Research Ethics*, Emanuel, E., Wendler, D., and Crouch, R. (eds), Oxford University Press, 2008, pp. 514-526.

11. King, N. M. P.: The Glass House: Assessing Bioethics. In *The Ethics of Bioethics*. Eckenwiler, L., and Cohn, F. (eds). Johns Hopkins University Press, 2007, pp. 297-309.

12. King, N. M. P.: Fame and Fortune: The "Simple" Ethics of Organ Transplantation. In *A Death Retold: Jesica Santillan, the Bungled Transplant, and the Paradoxes of Medical Citizenship*. Keith Wailoo, K. A., Julie Livingston, J., and Peter Guarnaccia, P. (eds). University of North Carolina Press, 2006, pp. 349-360.

13. King, N. M. P.: Genes and TS: What Will They Tell Us? Scientific, Ethical, and Social Implications. In Walkup, J. (ed.): *AIN: Tourette Syndrome*. Lippincott Williams & Wilkins, 2006, pp. 144-147.

14. King, N.M.P.: Glossary of Basic Ethical Concepts in Health Care and Research, in King, N. M. P., Strauss, R. P., Churchill, L. R., Estroff, S. E., Henderson, G. E., and Oberlander, J. (eds.): *The Social Medicine Reader (2nd ed.), volume 1: Patients, Doctors, and Illness*. Duke University Press, 2005, pp. 161-168.

15. Churchill, L. R., King, N.M.P., and Schenck, D.: Ethics in Medicine: An Introduction to Moral Tools and Traditions, in King, N. M. P., Strauss, R. P., Churchill, L. R., Estroff, S. E., Henderson, G. E., and Oberlander, J. (eds.): *The Social Medicine Reader (2nd ed.), volume 1: Patients, Doctors, and Illness*. Duke University Press, 2005, pp. 169-185.

16. King, N.M.P.: Privacy and Confidentiality in Research, in *Encyclopedia of Bioethics* (3rd ed., S. Post, ed.), MacMillan Publishing, 2004.

17. King, N.M.P.: Medical Research: Using a New Paradigm, *in Beyond Regulations: Ethics in Human Subjects Research*, (N. King, G. Henderson, J. Stein, eds) UNC Press, 1999, pp. 204-212.

18. King, N.M.P.: Research in Distressed Families, in *Beyond Regulations: Ethics in Human Subjects Research*, (N. King, G. Henderson, J. Stein, eds.), UNC Press, 1999, pp. 180-185.

19. King, N.M.P.: Privacy and Confidentiality in Research, in *Encyclopedia of Bioethics* (2nd ed., W. Reich, ed.), MacMillan Publishing, 1995, pp. 2060-2064.

20. King, N.M.P.: Consent to Treatment, in *Health Care Facilities Law* (A. Dellinger, ed.), Little, Brown, 1991, pp. 455-529.

21. Havighurst, C.C., and King, N.M.P.: Liver Transplantation in Massachusetts: Public Policymaking as Morality Play, in *Organ Transplantation Policy: Issues and Prospects* (J.F. Blumstein and F.A. Sloan, eds.), Duke University Press, 1989, pp. 229-260.

22. King, N. M. P.: Ethics Committees: Talking the Captain Through Troubled Waters, in *The Physician as Captain of the Ship: A Critical Reappraisal* (N. King, L. Churchill, A. Cross, eds.), D. Reidel Publishing, 1988, pp. 223-241.

23. King, N. M. P.: Federal and State Regulation of Neonatal Decisionmaking, in *Euthanasia and the Newborn* (R. McMillan, H.T. Engelhardt, S. Spicker, eds.), Reidel Co., 1987, pp. 89-116.

24. Cross, A. W., Churchill, L. R., Sharp, M. C., and King, N. M. P.: Ethical Issues in the Health Care of Children with Developmental Handicaps, *in Neurobiological Issues in Autism* (Shopler and Mesibov, eds.), Plenum, 1986, pp. 63-79.

Journal articles:

1. King NMP: Human Gene Editing Research: Is the Future Here Yet? *North Carolina L. Rev*. 2019;97:101-137.

2. King NMP, Bishop CE: Case & Commentary: How Should Physicians Help Patients Understand Unknowns of Nanoparticle-Based Medicines? *AMA J. Ethics* 2019;21:E324-331.

3. Coughlin C, King NMP, McKinney M: Regenerative Medicine and the Right to Try, *Wake Forest J Bus. Intellectual Property L.* 2018;590-637.

4. King NMP: Who's Winning the IRB Wars? The Struggle for the Soul of Human Research, *Persp. Biol. Med*. 2018;61:450-464.

5. King NMP: Research with Human Subjects: Humility and Deception, *IRB: Ethics & Hum. Res*. 2018; March-April:12-14.

6. Nageswaran S, Golden SL, Gower WA, King NMP. Caregiver Perceptions about their Decision to Pursue Tracheostomy for Children with Medical Complexity, *J. Pediatr*. 2018; DOI: 10.1016/j.jpeds.2018.07.045

7. Andrews JE, . . . King NMP, et al. Ensuring Respect for Persons in COMPASS: A Cluster Randomized Pragmatic Trial. *J. Med. Ethics* 2018;44:560-566.

8. Robeson R and King NMP: Performable Case Studies in Ethics Education, *Healthcare* 2017;5:57 doi:10.3390/healthcare5030057

9. King NMP and Bishop CE: New Treatments for Serious Conditions: Ethical Implications. *Gene Ther*. 2017;24:534-538. doi: 10.1038/gt.2017.32.

10. King NMP, Lord PC, and Lemley DE: Editing the Genome: Prospects, Progress, Implications, and Cautions. *Curr. Genet. Med. Rep*. 2017;5:35-43.

11. Hall MA and King NMP: Conscience, Courage, and "Consent," *Hastings Center Rep*. 46, no. 2 (2016): 30-32.

12. Baker, H. B., McQuilling, J. P., and King, N. M. P., Ethical Considerations in Tissue Engineering Research: Case Studies in Translation. *Methods*, 2016;99:135-144. http://dx.doi.org/10.1016/j.ymeth.2015.08.010

13. King, N. M. P., The Reasonable Patient and the Healer. *Wake Forest L. Rev*. 2015;50:343-361.

14. King, N. M. P., The Importance of Amicable and Productive Disagreement. *J. Med. Phil*. 2015;40:286-288. doi:10.1093/jmp/jhv004.

15. Friedmann T, Jonlin EC, King NMP, et al. ASGCT and JSGT joint position statement on human genomic editing. Mol Ther. 2015;23:1282.

16. King, N. M. P., and Iltis, A. S. Cell-Based Interventions in Utero: Time to Reconsider. Front. Pharmacol. 17 September 2014 | doi: 10.3389/fphar.2014.00214.

17. Robeson, R., and King, N. M. P., Loss of Possession: Concussions, Informed Consent, and Autonomy, *J Law Med Ethics* 2014;42:334-343.

18. King, N. M. P., and Perrin, J. E. Ethical Issues in Stem Cell Research and Therapy, *Stem Cell Res. Ther*. 2014;5:85-90.

19. Freedman, B. I, Fletcher, A. J., Sanghani, V. R., Spainhour, M., Graham, A. W., Russell, G. B., Cooke Bailey, J. N., Iltis, A. S., and King, N. M. P. Perceptions Regarding Genetic Testing in Populations at Risk for Nephropathy, *Am. J. Nephrol.* 2013;38:453-457.

20. Churchill, L. R., King, N. M. P., and Henderson, G. E. Why We Should Continue to Worry about the Therapeutic Misconception, *J Clin. Ethics* 2013;24(2)381-386.

21. Iltis, A. S., and King, N. M. P. (eds): Research Ethics: Reexamining Key Concerns, Special themed issue, *J. Law Med. Ethics* 2012;40:865-1024.

22. Henderson GE, Juengst ET, King NMP, Kuczynski K, Michie M. What Research Ethics Should Learn from Genomics and Society Research: Lessons from the ELSI Congress of 2011. *J. Law Med. Ethics* 2012;40:1008-1024.

23. Jones, J., and King, N. M. P. Bad Blood Thirty Years Later: A Q&A with James H. Jones. *J. Law Med. Ethics* 2012;40:867-872.

24. King, N. M. P. Nanomedicine First-in-Human Research: Challenges for Informed Consent. *J. Law Med. Ethics* 2012;40:823-830.

25. Fatehi L, Wolf S. M, . . . King N. M. P., et al. Recommendations for Nanomedicine Human Subjects Research Oversight: An Evolutionary Approach for an Emerging Field. J. Law Med. Ethics 2012;40:716-750

26. Corrigan-Curay J, Cohen-Haguenauer O, O'Reilly M, et al.: Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoetic stem cell gene therapy. *Mol. Ther.* 2012;20:1084-1094.

27. Walker R. L. and King, N. M. P..: Biodefense Research and the U.S. Regulatory Structure: Whither Nonhuman Primate Moral Standing? *Kennedy Inst. Ethics J* 2011;21:277-310.

28. King, N. M. P., Coughlin, C.N., Atala, A.: Pluripotent Stem Cells: the Search for the "Perfect" Source, *Minn. J. Law Sci. Technology* 2011;12:715-730.

29. Kent A, King N.M.P, and Cohen-Haguenauer O. Toward a proportionate regulatory framework for gene transfer: A patient group-led initiative. *Hum. Gene Ther*. 2011;22:126-134.

30. Coughlin, C.N., King, N.M.P., and Kemper, K. When doctors become patients: Advocating a patient-centered approach for health care workers in the context of mandatory influenza vaccinations and informed consent. *Wake Forest L Rev*. 2010;42:1551-1562.

31. Hall, M.A., Friedman, J.Y., King, N.M.P., Weinfurt, K.P., Schulman, K.A., and Sugarman, J. Per capita payments in clinical trials: Reasonable costs versus bounty hunting. *Acad. Med.* 2010;85:1554-56.

32. Robeson, R., and King, N.M.P. Contextualizing the Character-Violence Equation in Sports. *J Stud. Sports & Athletics in Ed*. 2010;4:27-42.

33. King, N.M.P., Coughlin, C., Furth M. Ethical issues in regenerative medicine. *Wake Forest Intellectual Property Law Journal* 2010;9:215-237.

34. Hall, M.A., King, N.M.P., Perdue, L.H., Hilner, J.E., Alkolar, B., Greenbaum, C.J., McKeon, C. Biobanking, consent, and commercialization in international genetics research: The Type 1 Diabetes Genetics Consortium. *Clinical Trials* 2010;166-173.

35. Hyde M.J. and King, N.M.P. Communication Ethics and Bioethics: An Interface. *Rev. Comm.* 2010;10:156-171.

36. Schaffer, R., Henderson, G., Churchill, L., King, N.M.P., Rothschild, B., Lohser, S., and Davis, A. (2009) Parents' online portrayals of pediatric treatment and research options. *Journal of Empirical Research on Human Research Ethics, 2009; 4*(3), 73-87.

37. Weinfurt, K.P, Hall, M.A., King, N.M.P., Friedman, J.Y., Schulman, K.A. and Sugarman, J. Disclosure of financial relationships in clinical research. *New England Journal of Medicine* 2009;361:916-921.

38. King, N.M.P. Benefits, harms, and motives in clinical research. *Hastings Center Report 2*009; 39(4), 3.

39. King, N. M. P, and Cohen-Haguenauer, O. En Route to Ethical Recommendations for Gene Transfer Clinical Trials, *Molecular Therapy* 2008;16:432-438.

40. King, N.M. P., and Robeson, R. Athlete or Guinea Pig? Sports and Enhancement Research, *Studies in Ethics, Law, and Technology* 2007;1:1-17. available online: <http://www.bepress.com/selt/vol1/iss1/art1>

41. Henderson, G. E., Churchill, L. R., Davis, A. M., Grady, C., Joffe, S., Kass, N., King, N. M. P., Lidz, C. W., Miller, F. G., Nelson, D. K., Peppercorn, J., Rothschild, B. B., Sankar, P., Wilfond, B. S., and Zimmer, C. Clinical Trials and Medical Care: Defining the Therapeutic Misconception, *PLoS Medicine* 2007;4:1735-1738.

42. Easter, M. M., G. E. Henderson, A.M. Davis, L. R. Churchill, King, N.M.P., "The Many Meanings of Care in Clinical Research." (2006) *Sociology of Health and Illness*, vol. 28, no. 6: 695-712; [and] in *The View From Here: Social Science and Bioethics*, edited by R. DeVries, L. Turner, K. Orfali, and C. Bosk (Oxford, UK: Blackwell Publishing Ltd. and *Sociology of Health and Illness*).

43. Kipnis, K., King, N. M. P., and Nelson, R. M.: Trials and Errors: An Open Letter to IRBs Considering Northfield Laboratories' PolyHeme Trial*. American Journal of Bioethics*. 2006; 6(3):1-4.

44. Kipnis, K., King, N. M. P., and Nelson, R. M.: Trials and Errors: Barriers to Oversight of Emergency Research. *IRB: Ethics & Human Research.* 2006;28(2:16-19, 2006.

45. Henderson, G. E., Easter, M. M., Zimmer, C., King, N. M. P., Davis, A. M., Rothschild, B. B., Churchill, L. R., Wilfond, B. S., and Nelson, D. K. Therapeutic Misconception in Early Phase Gene Transfer Trials. *Social Science and Medicine* 2006;62:239-53. Epub 2005 Jul 5.

46. King. N. M. P., Henderson G. E., Churchill L. R., Davis A. M., Hull S. C., Nelson D. K., Parham-Vetter P. C., Rothschild B. B., Easter M. M., and Wilfond B. S. Consent Forms and the Therapeutic Misconception: The Example of Gene Transfer Research. *IRB: Ethics & Human Research* 2005;27(1)1-8.

47. Henderson G. E., Davis A. M., King N. M. P. Vulnerability to Influence: A Two-Way Street. *American Journal of Bioethics* 2004;4(3):50-52.

48. Henderson G. E., Davis A. M., King N. M. P., Easter M. M., Zimmer C. R., Rothschild B. B., Wilfond B. S., Nelson D. K., and Churchill L. R.. Uncertain Benefit: Investigators' Views and Communications in Early Phase Gene Transfer Trials. *Molecular Therapy* 2004;10:225-231.

49. Churchill L. R., Nelson D. K., Henderson G. E., King N. M. P., et al. Assessing Benefits in Clinical Research: Why Diversity in Benefit Assessment Can Be Risky, *IRB: Ethics & Human Research* 2003;25(3):1-8

50. King N. M. P. The Line Between Clinical Innovation and Human Experimentation, *Seton Hall Law Review* 2003; 32:573-582.

51. King, N. M. P. Accident and Desire: Inadvertent Germline Effects in Clinical Research, *Hastings Center Report* 2003;33(2):23-30.

52. King, NMP. RAC Oversight of Gene Transfer Research: A Model Worth Extending?, *Journal of Law, Medicine & Ethics* 2002, 30: 381-389.

53. Henderson, G. E., and King, N. M. P.: Studying Benefit in Gene Transfer Research, *IRB: Ethics & Human Research* 2001;23(2):13-15.

54. King, N. M. P.: Defining and Describing Benefit Appropriately in Clinical Trials, *Journal of Law, Medicine & Ethics* 2000; 28: 332-343.

55. King, N. M. P., and Churchill, L. R.: Ethical Principles Guiding Research on Child and Adolescent Subjects, *Journal of Interpersonal Violence* 2000;15:710-724.

56. King, N. M. P.: Who Ate the Apple? A Commentary on *Core Competencies for Health Care Ethics Consultation: The Report of the American Society for Bioethics and Humanities (ASBH), HEC Forum* 1999;11:170-175.

57. King, N. M. P.: Rewriting the "Points to Consider": The Ethical Impact of Guidance Document Language, *Human Gene Therapy* 1999;10:133-139.

58. Dolan Kautz, B., Collings Hawkins, S., Scattoloni, J., and King, N. M. P.: *iris*: UNC Students Launch a Journal for Medicine, Literature, and Visual Art, *North Carolina Medical Journal* 1998;59:194-197.

59. Committee on Bioethics, AAP [J. Frader, J. Botkin, K. Moseley, R. Nelson, B. Wilfond, A. Kazura, W. Bowes, E. Krug, D. Caniano, N. King]: Statement: Female Genital Mutilation, *Pediatrics* 1998;102:153-156.

60. Churchill, L.R., Collins, M.L., King, N.M.P., Pemberton, S., and Wailoo K.: Genetic Research as Therapy: Implications of "Gene Therapy" for Informed Consent, *Journal of Law, Medicine and Ethics*, 1998;26:38-47.

61. Churchill, L.R., and King, N.M.P.: Physician-Assisted Suicide in the United States, *British Med J* 1997;315:137-138.

62. King, N.M.P., and Davis, A.M.: Advance Directives for Medical Decision Making in North Carolina: Rights, Duties, and Questions, *Popular Government*, 62(3):2-11 (Spring 1997) and 62(4):38-49 (Summer 1997).

63. King, N.M.P.: Research on Humans: What Have We Learned? *Forum for Applied Research and Public Policy*, 1997;12(3):132-136.

64. Committee on Drugs and Committee on Bioethics, AAP [C. Berlin, D. McCarver, D. Notterman, R. Ward, D. Weismann, G. Wilson, J. Wilson, E. Weller, D. Bennett, J. Mulinare, I. Hoskins, P. Kaufman, C. Krough, M. Rieder, G. Troendle, S. Yaffee, C. Coté, S. Szefler, J. Blumer, J. Frader, L. Crain, K. Moseley, R. Nelson, I. Porter, F. Vizcarrondo, W. Bowes, A. Kazura, E. Krug, D. Caniano, R. Dresser, N. King]: Statement: Considerations Related to the Use of Recombinant Human Growth Hormone in Children, *Pediatrics* 1997;99:122-129.

65. Committee on Bioethics, AAP [J. Frader, L. Crain, K. Moseley, R. Nelson, I. Porter, F. Vizcarrondo, W. Bowes, A. Kazura, E. Krug, D. Caniano, N. King]: Statement: Religious Objections to Medical Care, *Pediatrics* 1997;99:279-281.

66. Committee on Bioethics, AAP [J. Frader, L. Crain, K. Moseley, R. Nelson, I. Porter, F. Vizcarrondo, W. Bowes, A. Kazura, E. Krug, D. Caniano, N. King]: Statement: Ethics and the Care of Critically Ill Infants and Children, *Pediatrics* 1996;98:149-152.

67. King, N.M.P.: The Ethics Committee as Greek Chorus. *HEC Forum* 1996;8:346-354.

68. King, N.M.P., and Davis, A.M.: End of Life Decisionmaking: The Patient's Right to Choose, *North Carolina Medical Journal* 1996;57:381-384.

69. King, N.M.P.: Ethical and Legal Barriers to Futility Policies, *North Carolina Medical Journal* 1995;56:444-448.

70. King, N. M. P.: Experimental Treatment: Oxymoron or Aspiration? *Hastings Center Report*, 1995;25(4):6-15.

71. King, N.M.P.: Patient Waiver of Informed Consent, *North Carolina Medical Journal* 1993;54:399-403.

72. King, N.M.P.: Transparency in Neonatal Intensive Care, *Hastings Center Report* 1992;22(3): 18-25.

73. King, N.M.P.: Maternal-Fetal Conflicts: Ethical and Legal Implications for Nurse-Midwives, *Journal of Nurse-Midwifery* 1991;36:361-365.

74. King, N.M.P.: Dying Made Legal: New Challenge for Advance Directives, *HEC Forum* 1991;3:187-199.

75. King,, N.M.P., and Stanford, A.F.: Patient Stories, Doctor Stories, and True Stories: A Cautionary Reading, *Literature and Medicine* 1992;11(2): 185-199.

76. King, N.M.P., and Henderson, G.W.: Treatments of Last Resort: Informed Consent and the Diffusion of New Technology, *Mercer Law Review* 1991;42:1007-1050.

77. King, N.M.P., and Cross, A.W.: Children as Decision-Makers: Guidelines for Pediatricians, *Journal of Pediatrics* 1989;113:10-16.

78. King, N. M. P., Hunter, W., and Runyan, D. K.: Going to Court: Observing the Court Experiences of Child Victims of Intrafamilial Sexual Abuse, *Journal of Health Politics, Policy, and Law* 1988;13:705-721.

79. Havighurst, C., and King, N. M. P.: Liver Transplantation in Massachusetts: Public Policymaking as Morality Play, *Indiana Law Review* 1987;19:955-987.

80. Coulter, M. L., Runyan, D. K., Everson, M. D., Edelsohn, G. A., and King, N. M. P.: Conflicting Needs and Interests of Researchers and Service Providers in Child Sexual Abuse Cases, *Child Abuse and Neglect* 1985;9:535-542.

81. Havighurst, C., and King, N.M.P.: Private Credentialing of Health Care Personnel: An Antitrust Perspective, Part II, *American Journal of Law and Medicine* 1983;9:263-334.

82. Havighurst, C., and King, N. M. P.: Private Credentialing of Health Care Personnel: An Antitrust Perspective, Part I, *American Journal of Law and Medicine* 1983;9:131-201.

83. King, N. M. P.: Ensuring Informed Consent in Human Experimentation: Two States' Approaches, *N.C.L. Rev.* 1979;58:137-152.

84. King, N. M. P.: Rights of the Mentally Retarded: Halderman v. Pennhurst Closes State Institution and Mandates Community Care, *N.C.L. Rev.* 1979;57:336-350.

Miscellaneous (Selected):

1. King, N. M. P. Who's Winning the IRB Wars? The Struggle for the Soul of Human Research, *Persp. Biol. Med*. 2018;61:450-464.

2. King, N. M. P. On Patients, Prescriptions, and Profits. Review: Sharon Batt, Health Advocacy, Inc: How Pharmaceutical Funding Changed the Breast Cancer Movement, UBC Press, 2017. *Indian J Med. Ethics* 2018;3:168.

3. King, N.M.P. Speaking about Silence: The Need to Hear from Research Subjects, *IRB: Ethics Hum. Res*. 2017;39(5)19-20.

4. Robeson, R., and King, N. M. P. The Limits of Fairness — Ethics and Gender Equity in Football, *Concussion Policy & the Law – Sports Industry News and Analysis*, May 9, 2016. http://concussionpolicyandthelaw.com/2016/05/09/the-limits-of-fairness-ethics-and-gender-equity-in-football/

5. Robeson, R., and King, N. M. P. The NFL Concussion Settlement and the Ethics of Informed Choice, *Concussion Policy & the Law – Sports Industry News and Analysis*, Feb. 24, 2016. http://concussionpolicyandthelaw.com/2016/02/24/the-nfl-concussion-settlement-and-the-ethics-of-informed-choice/

6. King, N. M. P. Review: Erik Parens, Shaping Our Selves: On Technology, Flourishing, and a Habit of Thinking, Oxford University Press, 2014. *Kennedy Inst. Ethics J*. 2016, online publication: https://kiej.georgetown.edu/book-reviews/archive/parens-2014/

7. King, N. M. P., Book Review of Moral Entanglements: Ancillary-Care Obligations of Medical Researchers, *J. Moral Phil* 2015;12:787-805.

8. King, N. M. P. There's a Lot We Don't Know (and We Ought to Say So), *Am. J. Bioeth.* 2013;13(12)20-21.

9. King, N. M. P., and Robeson, R. Athletes Are Guinea Pigs, *Am. J. Bioeth*. 2013;13(10):13-14.

10. Macklin, R., Shepherd, L., Dreger, A., ...King, N. M. P., et al. The OHRP and SUPPORT -- Another View (correspondence), *NEJM* 2013;369(2):e3.

11. King, N. M. P.: Pragmatism, Value, and Judgment in Medicine: A Review of Means, Ends and Medical Care, Philosophy & Medicine, vol. 92, by H. G. Wright, M.D, Ph.D. J Law Med Ethics 2009;37:419-20.

12. AAMC Task Force, Industry Funding of Medical Education, June 2008. Report available online at: <https://services.aamc.org/Publications/showfile.cfm?file=version114.pdf&prd_id=232&prv_id=281&pdf_id=114>

13. King, N. M. P. The Healthy Patient Paradox in Clinical Trials. Atrium 2008;5:9-11. http://bioethics.northwestern.edu/atrium/atrium_issue5.pdf

14. King, N. M. P., The Ethics of Genetic Testing: Is More Always Better? *NC Med J* 2007;68:112-114.

15. NIH Office of Biotechnology Activities. NIH Guidance on Informed Consent for Gene Transfer Research. 2004 http://www4.od.nih.gov/oba/rac/ic/

16. King, N. M. P., The Stories We Tell Ourselves, *Hastings Center Report* 2003;33(5):49.

17. Henderson, Gail E. and N. M. P. King, Perceived Benefits of Participation in Gene Transfer Research. *HemAware* 2002;7(5):73-75

18. King, N. M. P.: Patient or Guinea Pig? *Guinea Pig Zero* 2000; 8:18-24.

19. King, N.M.P.: "The Natural Death Act: A Philosophical Context for a Practical Problem," *North Carolina State Bar Quarterly* 1992;39(1): 12-17.

20. Cross, A. W., and King, N. M. P.: Moral and Legal Issues in Screening for Drug Use in Adolescents (editorial), *Journal of Pediatrics* 1987;111:249-250.

INVITED PRESENTATIONS (Selected Recent):

"From the Bench to the Bedside: A 50-Year Journey," Wake Forest University Center for Bioethics, Health, and Society Conference, Beyond Our Beginnings: 50 Years of Bioethics, Winston-Salem, NC (April 5, 2019)

"Why Emotion Is Integral to Cognition," panel presentation, Wake Forest Law Review Symposium on Cognitive Emotion and the Law, Winston-Salem, NC (February 22, 2019)

"What's New in the New Common Rule?" Ethics Grand Rounds, Loma Linda University Health, Loma Linda, CA (February 20, 2019)

"Gun Safety, Gun Research, and Law," panel presentation, American Society for Bioethics and Humanities Annual Conference, Anaheim, CA (October 20, 2018)

"Science Fiction, Human-Machine Interfaces, and Teaching Undystopianization," paper presentation, American Society for Bioethics and Humanities Annual Conference, Anaheim, CA (October 18, 2018)

"Human Gene Editing Research: Is the Future Here Yet?" panel presentation, North Carolina Law Review Symposium on Legal, Ethical, and Policy Implications of New Gene Editing Technologies, Chapel Hill, NC (October 5, 2018).

"What Science Fiction Can Teach Us about the Human Condition," European Society for the Philosophy of Medicine and Healthcare Annual Conference, Lisbon, Portugal (August 25, 2018).

"Science, Society, and Charile Gard," panel presentation (with Chris Coughlin), Health Law Professors Conference, Cleveland, OH (June 9, 2018).

"Translational Regenerative Medicine Research: Ethics Overview." 2018 Regenerative Medicine Essentials Course, Winston-Salem, NC (June 7, 2018).

"Autonomy and Beneficence in the Hospital: When the Team Says 'Let's Go' but the Patient Says 'No'," Novant Health Ethics Education Conference, "Taking it to the Limit: How Far Will we Go to Get Patients to Do What We Think Is Right?" Forsyth Hospital, Winston-Salem, NC (April 30, 2018).

"Biotechnology Research Design & Subject Selection: Implications for IRBs?" WIRB-Copernicus Group Spring Training Conference, Cary, NC (March 28, 2018).

"Regulating Genetic Engineering: Drawing Lines in Wind and Water?" panel presentation, University of Pennsylvania Journal of Law & Public Affairs Symposium, "Regulation of Genetic Engineering," Penn Law, Philadelphia, PA (February 10, 2018).

"Ethical and Policy Issues in Organ Generation and Regeneration," panel presentation, Wake Forest Journal of Business & Intellectual Property Law Symposium, "Intellectual Property & Medical Technology," Wake Forest Biotech Place, Winston-Salem, NC (February 2, 2018).

"The New Common Rule and the Biotech Future of Human Research," Keynote Presentation, Conference on Ethics and Compliance in Human Subjects Research: New Challenges under the Revised Common Rule, Arizona State University, Phoenix, AZ (September 16, 2017).

"Genome Editing: Who (Really) Needs It?" Genome Editing Conference, Belgrade Center for the Study of Bioethics/Hastings Center/NYU, Belgrade, Serbia (August 21, 2017).

"They're Going to CRISPR People!" European Society for the Philosophy of Medicine and Healthcare Annual Conference, Belgrade, Serbia (August 17, 2017).

Panelist, "Session 5: Future Role of the RAC," in Workshop, NIH Guidelines: Honoring the Past, Charting the Future, Bethesda, MD (July 19, 2017).

"Regenerative Medicine and the Meaning of Success," International Association of Law and Mental Health Biennial Conference, Prague, Czech Republic (July 11, 2017)

Panelist, "Session VII: Ethics Panel Wrap-Up: What is the Future of Accelerated Development and the Randomized Controlled Trial Standards?" in Conference, The Need to Accelerate Therapeutic Development: Must Randomized Controlled Trials Give Way? New York Academy of Sciences, New York, NY (June 22, 2017).

"What's New in the New Common Rule," panel presentation, Health Law Professors Conference, Atlanta, GA (June 9, 2017).

"Translational Regenerative Medicine Research: Ethics Overview." 2017 Regenerative Medicine Essentials Course, Winston-Salem, NC (June 8, 2017).

"Regenerating and Replacing Organs: Research Ethics and Policy Issues," American Urological Association Basic Science Symposium, Boston, MA (May 12, 2017).

"The Case Study in Dialogic Form – Ethical Imperatives and Caveats" (with Richard Robeson), American Medical Writers Association Carolinas Chapter Spring Conference, Chapel Hill, NC (May 5, 2017).

"Biospecimens under the New Common Rule: "Broad Consent" and Beyond." Department of Pathology Grand Rounds, Wake Forest Baptist Medical Center, Winston-Salem, NC (April 5, 2017).

"Translational Regenerative Medicine Research: Ethics Overview." 2016 Regenerative Medicine Essentials Course, Winston-Salem, NC (July 14, 2016).

"So What Else Is New? Comparing Ethical Issues in Clinical Translation of 3D Bioprinting With Other Novel Regenerative Biotechnologies." Workshop, 3D Bioprinting: A New Medical and Ethical Frontier? Brocher Foundation, Geneva, Switzerland (May 24, 2016).

"Why BSS & Bioethics & Medical Humanities Belong Together in 21st Century Medical Education." Integrating Behavioral & Social Sciences [BSS] into Healthcare Education Dissemination Meeting, Natcher Auditorium, NIH, Washington, DC (April 22, 2016).

"The Ethics of Research with Human Subjects: Introduction, Background, and History." SUNY Downstate Medical Center, Brooklyn, NY (March 9, 2016).

" Ethics in Regenerative Medicine: What's Old, What's New, What's Borrowed & What's Blue Sky?" University of Pittsburgh Pittsburgh, PA (Nov. 12, 2015).

"Categorically No: 'Upstream' Decisions on Screening, Testing, and Treatment," Clinical Ethics Network of North Carolina Annual Conference, Asheville, NC (Sept. 18, 2015).

“Concussion and Consent in Football: The View from Bioethics” (with Richard Robeson), Lexington Kiwanis Club, Lexington, NC (Sept. 3, 2015).

“The Medicalization of Everything,” European Society for the Philosophy of Medicine and Healthcare Annual Conference, Gent, Belgium (Aug. 22, 2015).

“Translational Regenerative Medicine Research: Ethics Overview,” WFIRM Regenerative Medicine Essentials Course, Winston-Salem, NC (July 23, 2015).

Invited Presentation, “Learning Health Care Systems: Promises and Perils for Human Subjects Protections,” Greater Charlotte ACRP Meeting, Charlotte, NC (June 9, 2015).

Panel Presentation, “Learning Health Care Systems and Human Subjects Protections,” ASLME Health Law Professors Conference, St. Louis, MO (June 6, 2015).

Invited Panel Presentation, “Randomization Alters Risk,” IOM Workshop on Ethical Review and Oversight Issues in Research Involving Standard of Care Interventions, Washington, DC (December 2, 2014)

Invited Panelist, “Enrollment Issues for Clinical Trial Participants,” NIH Workshop on the Enrollment and Retention of Participants in NIH-Funded Clinical Trials, Bethesda, MD (July 25, 2014).

“Translational Regenerative Medicine Research: Ethics Overview,” WFIRM Regenerative Medicine Essentials Course, Winston-Salem, NC (July 24, 2014).

“From the Bench to the Bedside: Ethics and Policy in Translational Biotechnology Research,” Hacettepe University School of Medicine, Ankara, Turkey (May 22, 2014).

“’Informed’ Consent in Team Sports: The View from Bioethics” (with Richard Robeson), Invited Presentation, Wake Forest Baptist Medical Center Clinical Ethics Committee, Exploring Ethics Lecture Series, Winston-Salem, NC (May 6, 2014).

“Ready or Not: Ethical Dimensions of Hospital Discharge,” Invited Conference Presentation, Ethics in Practice from Bedside to Boardroom, CENNC Conference, Friday Center, Chapel Hill, NC (Feb. 21, 2014).

Panel Presentation, “Ethical Controversies in Research on Standard of Care: The SUPPORT Study,” Research Ethics Grand Rounds, UNC School of Medicine, Chapel Hill, NC (Nov. 19, 2013).
Panel Presentation, “Legal Update,” American Society for BIoethics and Humanities Annual Meeting, Atlanta, GA (Oct. 26, 2013).

“Regenerative Medicine and the ‘New Normal,’” European Society for the Philosophy of Medicine and Healthcare Annual Meeting, Basel, Switzerland (Aug. 15, 2013).

“Ethical Issues in Cell- and Gene-Based Research and Therapy,” International Society for Stem Cell Research Annual Meeting, Boston, MA (June 14, 2013).

“Health Disparities, Race/Ethnicity, and Genes: How Data Interpretation and Dissemination Can Go Wrong,” Annual Women’s Health Initiative Investigator Meeting, Seattle, WA (May 3, 2013).

“Faith in Science: Ethical Implications,” After the Genome conference, Wake Forest University (April 11, 2013).

Panel presentation, Scarred for Life conference, Wake Forest University (April 5, 2013).

Closing remarks, HerStories Symposium, W Wake Forest University (March 2, 2013).

“Ethical and Policy Issues in Biobanking and Biospecimen Research,” Pathology Grand Rounds, Wake Forest Baptist Medical Center, Winston-Salem, NC (December 5, 2012).

“Individualized Genomic Medicine: Is It Fair?” Invited presentation, Trent Center for Bioethics, Humanities, and History of Medicine, Duke University, Durham, NC (December 5, 2012).

“Overlapping Ethical Issues in Cell and Gene Therapies,” Invited presentation, European Society for Gene and Cell Therapy Annual Conference, Versailles, France (October 28, 2012).

“Readers’ Theater: An Innovative Method for Ethics Education,” Workshop, ASBH Annual Meeting, Washington, DC (Oct. 19, 2012).

“Individualized Genomic Medicine: Is It Fair?” Invited presentation, UNCC Center for Professional and Applied Ethics, Charlotte, NC (September 19, 2012).

“Risk-Benefit Assessment and Research Ethics Committees,” invited symposium panelist, International Association of Bioethics, 11th World Congress of Bioethics, Rotterdam, Netherlands (June 29, 2012).

"Better Babies?" Invited presentation, UNCC Center for Professional and Applied Ethics, Charlotte, NC (April 4, 2012).

“Why Don’t We Agree About End-of-Life Decisions? And What Can We Do About It?” Invited presentation, Wake Forest Baptist Medical Center Clinical Ethics Committee, Exploring Ethics Lecture Series, Winston-Salem, NC (March 8, 2012).

“Stem Cell Banking: Ethical and Policy Issues,” Invited Presentation, Qatar Foundation-Baker Institute, International Conference on Stem Cell Science and Policy, Doha, Qatar (February 28, 2012).

“Human Parts/Corporate Profits: Modern Research Ethics and Lessons from Henrietta Lacks.” with Richard Weinberg and Joseph Andrews. WFBMC (December 6, 2012).

“Key Ethical Issues in First-in-Human Gene Transfer Trials,” Invited presentation, European Society for Gene and Cell Therapy Annual Meeting, Brighton, England (October 28, 2011).

“Law and Bioethics: Asking the Right Questions,” Invited presentation, Navigating the Law in Ethics Teaching and Ethics Consultation, Preconference Workshop, ASBH Annual Meeting, Minneapolis, MN (Oct. 13, 2011).

“Nanomedicine First-in-Human Research: Challenges to Informed Consent,” Invited presentation, Nanodiagnostics & Nanotherapeutics: Building Research Ethics & Oversight Conference, Minneapolis, MN (Sept. 26, 2011).

“Genetics and Ethics: A Decade after the Completion of the Human Genome Project,” Invited presentation, Milwaukee Academy of Medicine, Milwaukee, WI (Sept. 20, 2011).

“Connecting the I’s: The Challenge of Novel Biotechnologies,” Invited presentation, The Three I’s and Bioethics: IACUCs, IRBs, & IBCs, Conference, NCABR/MSMR Conference, Chapel Hill, NC (Sept. 19, 2011).

“Why Don’t We Agree About End-of-Life Decisions? And What Can We Do About It?” Invited presentation, UNC-Chapel Hill Center for Bioethics/Hospital Ethics Committee Clinical Ethics Grand Rounds, Chapel Hill, NC (Sept. 9, 2011).

“Early-Phase Research: Science or Treatment?” Invited presentation, ASLME Health Law Professors Annual Meeting, Chicago, IL (June 11, 2011).

"The Research Orientation of Early-Phase Clinical Trials," Invited panel presentation, American Society of Clinical Oncology Annual Meeting, Chicago, IL (June 5, 2011).

"Consent to What?! Ethical and Policy Issues in Biobanking and Biospecimen Research" and "Regenerative Medicine Research: Questions New and Old." Invited presentations, FLACSO Fogarty International Annual Research Ethics Workshop, Buenos Aires, Argentina (May 30-June 4, 2011).

"Evaluating and Valuing Personalized Genomic Information." Invited panel presentation, American Society for Gene and Cell Therapy Annual Meeting, Seattle, WA (May 19, 2011).

"Consent to What?! Ethical and Policy Issues in Biobanking and Biospecimen Research." Invited presentation, Semi-Annual Lecture Series, McGlll University Health Centre, Montreal, Canada (May 13, 2011).

"First-in-Human Trials and the Research-Treatment Distinction: Bright Line, Blur, or Bust?" Invited presentation, Biomedical Ethics Unit, McGill University, Montreal, Canada (May 12, 2011).

"Early-Phase Trial Design and Ethics: Lessons from Gene Transfer and Regenerative Medicine Research," Invited presentation, CliniGene Network of Excellence State of the Art Conference, Ethics & Regulatory Roundtable Presentation, Paris, France (April 8, 2011).

"Honoring Choices at the End of Life: MOST and More." End of Life: Getting Wishes Honored – Why It Doesn't Happen -- and the Benefits of Palliative Care. Panel Presentation, 15th Annual Elder Law Symposium, NC Bar Center, Cary, NC (Feb. 25, 2011).

Genetic Research Meets Critical Race Theory: A Case Study toward Eliminating Healthcare DIsparities. Center for Professional and Applied Ethics, UNCC, Charlotte, NC (Feb. 22, 2011).

"Health Equity and Regenerative Medicine." Panel presentation, Regenerative Medicine: Should We Seek to LIve Forever? Center for Professional and Applied Ethics, UNCC, Charlotte, NC (Feb. 3, 2011).

"Genes, Race, and Health DIsparities: What are We Thinking?" Division of Public Health Sciences Seminar, Wake Forest University Health Sciences, Winston-Salem, NC (Jan. 20, 2011).

Phase I Trials for Adult and Pediatric Disease: Ethics, Design, & Decisions. RAC-CliniGene Conference on Retroviral and Lentiviral Vectors for Long-Term Gene Correction, Bethesda, MD (Dec. 10, 2010)

"Genetic Research and Stored Biological Specimens" and "Ethical Issues When Conducting Research on Residual Newborn Screening Blood Samples" PRIM&R Advancing Ethical Research Conference, San Diego, CA (Dec. 6&7, 2010)

"Regenerative Medicine Research: System-Level Ethics." Panel presentation, American Society of Bioethics and Humanities Annual Meeting, San Diego, CA (Oct. 22,. 2010)

"Potential Benefits and RIsks of Harm in Synthetic Biology: Some Basic Observations." Invited Presentation, Presidential Commission for the Study of Bioethical Issues, Washington, DC (July 8, 2010).

"The Ethics of Research with Human Subjects: Introduction Background, and History," "Ethical Responsibilities of the Physician Researcher," "Assessing Potential Benefits and Risks of Harm," and "Informed Consent, Assent, and Waiver: International Implications," Invited Lectures, Croatian Conference on Clinical Research Ethics, Zagreb, Croatia (April 29&30, 2010).

"Genetic Manipulation in Regenerative Medicine: Research Ethics Reminders & Recommendations. Invited Presentation, European Society for Gene and Cell Therapies Combined Meeting", Hannover, Germany (Nov. 23, 2009).

"The Siren Song of Benefit: First-in-Human Trials of Novel Biotechnologies." Annual Conference, European Society for the Philosophy of Medicine and Healthcare, Tubingen, Germary (August 21, 2009).

"Improving Informed Consent," Invited Presentation, Protocol Review Committee, Hoffman-LaRoche, Basel, Switzerland (August 18, 2009).

"The Ethics of Research with Human Subjects: Introduction Background, and History," "Ethical Responsibilities of the Physician Researcher," "Assessing Potential Benefits and Risks of Harm," and "Informed Consent, Assent, and Waiver: International Implications," Invited Lectures, Romanian Conference on Ethics in Clinical Research, Bucharest, Romania (July 7&8, 2009).

"Selecting and informing patient-subjects in gene transfer clinical trials: uncertainty and disagreement about balancing harms and benefits." Invited Presentation, Gene Transfer Clinical Trials: A CLINIGENE Patients' Group Workshop: Toward a proportionate regulatory framework for gene transfer clinical trials, Abbaye de Royaumont, France (March 7, 2009).

"Biobanking & Confidentiality: Information & Expectations," Invited Presentation, Questions About Research Ethics Conference, Mt. Sinai School of Medicine, New York, NY (March 6, 2009).

"Ethical Issues in Regenerative Medicine Research," Invited Presentation, Wake Forest Intellectual Property Law Journal Symposium on Regenerative Medicine, Winston-Salem, NC (February 6, 2009).

"Brave New Genetic Universe: Information and Expectations," Invited Presentation, Panel XIII, Privacy and Risk in 'Brave New World, Technologies, PRIM&R Advancing Ethical Research Conference, Balancing the Needs of Human Subjects and Science, Orlando, FL (November 19, 2008)

"Using the Stratification Scheme: Prerequisites for First-in-Human Gene Transfer Clinical Trials," Invited Presentation, European Society for Gene and Cell Therapy Annual Conference, Brugge, Belgium (November 15, 2008).

"If We Tell the Truth, They Won't Enroll," Invited Presentation, Greater Charlotte ACRP Annual Conference, Subject Recruitment & the Public Perception of Research: Practical and Ethical Considerations, Charlotte, NC (October 31, 2008).

"Who's Minding the Specimen Store? Rights & Duties, Expectations & Prospects," Panel Presentation, ASBH Annual Meeting, Cleveland, OH (October 24, 2008)

"The Electronic Health Record in Research: Ethical Implications," Invited Presentation, Wake Forest University TSI Conference on Health Analytics, The Electronic Health Record: Best Practices and New Horizons, Winston-Salem, NC (October 3, 2008).

"Ethics in Translation: Issues in Genomics Research and DNA Banking," Invited Lecture, TSI Phenotype Course, WFU (June 26, 2008).

"Academic Bioethics: Utility Infielders, Superspecialists, and Usual Suspects," State of the Field Panel, Bioethics Summer Retreat, Santa Rosa, CA (June 18, 2008).

"The Trouble With Futility," Internal Medicine Grand Rounds, WFUSM (May 15, 2008).

"Describing benefit in consent forms: lessons from gene transfer research," Translating "ELSI": Ethical, Legal and Social Implications of Genomics Congress, Cleveland, OH (May 3, 2008).

"Biobanking and Pediatrics: Genetic Research and Beyond," Invited Lecture, Ethical Dilemmas in Research Involving Children, SUNY Downstate Conference, Brooklyn, NY (April 29, 2008).

"Therapeutic Overestimation in Early-Phase Trials," Invited Lecture, McGill University Bioethics Unit, Montreal (April 25, 2008).

"Health Disparities, Value Silos, and the Trouble With 'Futility'," Invited Lecture, Speas Colloquium, Davidson College, NC (April 5, 2008).

"Health Care: Is the Best Always the Enemy of the Good?" invited presentation, Worried Sick: Human Values and Reforming American Health Care, UNC Program in Humanities and Human Values Seminar, Chapel Hill, NC (March 1, 2008).

What Do the Havasupai Tribe Have to Do with My DNA? Invited Lecture, UNC-Charlotte and Bioethics Resource Group, Charlotte, NC (March 6, 2008).

"Pluripotent Stem Cells: Scientific, Ethical, and Policy Issues." Invited Lecture, Triangle Area Research Directors' Council, Research Triangle Park, NC (November 13, 2007).

"Balancing on the Cutting Edge: Ethical Issues in Cognition Research," Invited Lecture, Continuing the Dialogue: Cutting Edge Translational Research, 11th Biennial Graylyn Conference on Women's Cognitive Health, Winston-Salem, NC (October 26, 2007).

"Children and Medical Emergencies: Ethical Challenges". Invited Lecture, Children First, Brenner Children's Hospital Acute Care Symposium, , WFUBMC (June 8, 2007).

"The Ethics of Research Using Human Subjects: An Introduction," and "Informed Consent and Understanding in Research with Human Subjects," Invited Lectures, Central Asian Workshop on the Contribution of Research Ethics to the Development of National Health Research Systems, Kazakhstan School of Public Health, Almaty, Kazakhstan (May 7, 2007).

"Genetic Biospecimen Research and Biobanking: Questions and Context", Invited Lecture, VA Hospital, Salisbury, NC (February 15, 2007).

"Conflicts of Interest in Clinical Research: Two Case Examples," Invited Workshop, UNC-C, Charlotte, NC (February 8, 2007).

"Potential Benefits and Risks of Harm: Understanding in Context," Invited "Risk" Panel Presentation, PRIM&R 2006 Annual Human Research Protections Programs Conference, A Commitment to Ethical Research, Washington, DC (Nov. 17, 2006).

"Ethical and Legal Issues Related to Human Specimens and Data", Co-Presenter, Didactic Workshop, PRIM&R 2006 Annual Human Research Protections Programs Conference, A Commitment to Ethical Research, Washington, DC (Nov. 17, 2006).

"Ethical Issues in Gene Transfer Research: Informed Consent and More," Invited Speaker, ESGT Annual Meeting, Athens, Greece (Nov. 10, 2006).

"The PolyHeme Trial: Risk & Consent in Emergency HBOC Research", Invited Speaker, Ethics Program, AABB Annual Meeting, Miami, FL (October 23, 2006).

"The PolyHeme Trial: What Went Wrong? (How Do You Define 'Wrong'?,) Faculty Seminar, MacLean Center for Clinical Medical Ethics, University of Chicago School of Medicine, Chicago, IL (October 3, 2006).

"The PolyHeme Trial: What Went Wrong? (How Do You Define 'Wrong'?) Bresnahan Colloquium, Medical Humanities and Bioethics Program, Northwestern University Fineberg School of Medicine, Chicago, IL (October 3, 2006).

"Understanding & Consent in Research: Lessons from Gene Transfer", Invited Lecture, Rush University Medical Center, Chicago, IL (October 3, 2006).

"Ethics, Time, and Money in Emergency Research," Invited Panelist, Biotechnology: Innovation, Funding, and Ethics Conference, Wake Forest University, Winston-Salem, NC (Sept. 29, 2006).

"Reviewing Emergency Research: Ethical Considerations for IRBs", Invited presentation, "Crossing the Line: What is Acceptable Risk?" National Human Subject Protections Conference, Durham, NC (Sept. 25, 2006).

"Ethical Issues in Gene Transfer Research: What Investigators, Sponsors, and Oversight Bodies Need to Know," Panelist, "Procedural and Substantive Issues in Oversight of Gene Transfer Research: IRB Review, IBC Review, and Ethics, BIO 2006, Chicago, IL (April 10, 2006).

"Informed Consent and the Therapeutic Misconception in Hospital-Based Clinical Trials: Why Dotting the "I"s and Crossing the "T"s Matters," and "Genetic Research in Social Context," Invited Lectures, Second Annual Catholic Healthcare West Human Research Protection Office Research Conference, Phoenix, AZ (April 6, 2006).

"Ethical Issues in Gene Transfer Research: Informed Consent and More," Invited Keynote Lecture, CLINIGENE Network of Excellence Kick-Off Conference, Annecy, France (April 1, 2006).

"Doctor Frankenstein, I Presume? Why the Investigator-Subject Relationship is a Problem for the Physician-Patient Relationship, and Vice Versa," Invited Lecture, Frederick Womble Speas Symposium, "Problematic Physicians, Problematic Patients," Davidson College, Davidson, NC (March 17, 2006).

"Talking about Benefits in Clinical Research: An Analysis and Assessment," Invited Lecture, Wake Forest University School of Medicine, Winston-Salem, NC (March 14, 2006).

"Protecting Human Subjects, Promoting Good Research: Overview of Ethical Principles & US Regulations." Lecture, Conference and Forum Discussion on Ethical Review of Clinical Research in Poland, Warsaw (January 21, 2006).

"Review of Bioterrorism, "Dual-Use", and/or Biodefense Resarch" Co-Presenter, Didactic Workshop, PRIM&R 2005 Annual Human Research Protections Programs Conference, Ethics and Trust Across Boundaries, Boston, MA (December 5, 2005).

"Risks of Harm & Potential Benefits in Research: A Primer". Invited Lecture, Conference on Emerging Issues in Research with Human Subjects, National Institute of Environmental Health Sciences, Research Triangle Park, NC (September 23, 2005).

"Athlete or Guinea Pig? Sports and Enhancement Research." Refereed Panel Presentation (with Richard Robeson), 19th Annual European Conference on the Philosophy of Medicine and Health Care, Ethics and Regulation of Emerging Medical Technologies, Barcelona, Spain (August 27, 2005).

"Children in Gene Transfer Trials: Design, Benefit, and Consent Issues," Invited Panel Presentation, Scientific Symposium on Informed Consent and Children, American Society of Gene Therapy 8th Annual Meeting, St. Louis, MO (June 3, 2005).

"Ethical Issues in Collecting and Using Biospecimens in Population Research," Invited Lecture, Carolina Population Center, UNC-Chapel Hill, NC (February 25, 2005).

"Responsible Conduct of Research: The Havasupai Tribe Case," Invited Workshop, UNC-C, Charlotte, NC (February 18, 2005).

"Talking about Benefits in Clinical Research: A Candid Assessment," Invited Lecture, Charlotte Chapter ACRP, Charlotte, NC (February 17, 2005).

"Hope in Clinical Trials," Panel Presentation, American Society for Bioethics and Humanities Annual Meeting, Philadelphia, PA (October 30, 2004).

"Informed Consent in Clinical Trials: Lessons from a Content Analysis of Gene Transfer Consent Forms," Invited Presentation, Hoffman-La Roche, Basel, Switzerland (October 13, 2004).

"Genetic Research and the Germline: Accident or Desire?" and "Informed Consent in Gene Transfer Research: Report of a Study," Panel Presentations, Genetics and Health Care, International ELSAGEN Conference on Ethical, Legal and Social Aspects of Human Genetic Databases and the 18th Annual European Conference on Philosophy of Medicine and Health Care, Reykjavik, Iceland (August 26, 2004).

"Research Harms and Benefits Across Cultures: The Basics" and "Biospecimen Research in Social Context", Invited Presentations, RTI/FHI Conference, Roadmap for Success in International Research: Strategies for Protecting Human Subjects Globally, Chapel Hill, NC (August 2 & 3, 2004).

"Genes and Tourette Syndrome: What Will They Tell Us? Ethical, Legal, and Social Implications," Invited Presentation, Fourth International Scientific Symposium on Tourette Syndrome, Cleveland, OH (June 26, 2004).

"Relationships in Research: Human Reality, Ethical Challenge," Invited Presentation, Traditional Knowledge and Research Ethics Conference, National Institute of Research Excellence in Maori Development and Advancement, Wellington, NZ (June 11, 2004).

"Informed Consent in Gene Transfer Research: Lessons for Early-Phase Clinical Trials," Invited Plenary Panel Presentation, Fourth National Medical Research Summit, Baltimore, MD (April 22, 2004).

"Distinguishing Research from Treatment," Invited Presentation, Informed Consent Workshop, BMT Tandem Meetings, Lake Buena Vista, FL (February 16, 2004).

"Social Construction of Benefit in Gene Transfer Research", Invited Presentation, NHGRI IRB/SRC Retreat, College Park, MD (January 29, 2004).

"What Subjects & Researchers Expect and Consent Forms Say About Benefit in Gene Transfer Research", Invited 'Beneficence' Panel Presentation, PRIM&R Annual Meeting, Washington, DC (December 6, 2003).

"Oversight and Harm-Benefit Information in Gene Transfer Research," Invited Presentation, ABA/AMA/AAAS Conference, "Working at the Frontiers of Law and Science: Applications of the Human Genome, Chapel Hill, NC (October 2-3, 2003).

"What Consent Forms Say in Gene Transfer Research", Invited Presentation, Recombinant DNA Advisory Committee, Bethesda, MD (June 19, 2003).

"Bioethics and Conflicts of Interest," Invited Presentation, Clinical Gene Transfer Review Course, American Society of Gene Therapy Annual Meeting, Washington, DC (June 3-4, 2003).

"Informed Consent in Hemophilia Gene Transfer Research," Invited Presentation, Human Gene Therapy Workshop, National Hemophilia Foundation, La Jolla, CA (April 26, 2003).

"Informed Consent: What the Rules Say and How It Should Work," Workshop for Research Ethics and Institutional Review Boards, Beijing, PRC (Mar. 11, 2003).

"The Ethics of Research Using Human Subjects: Interpreting Common Principles," Workshop for Research Ethics and Institutional Review Boards, Beijing, PRC (Mar. 10, 2003).

"Guinea Pig or Patient?" Invited Lecture, Center for Professional and Applied Ethics, The University of North Carolina at Charlotte, Charlotte, NC (Mar. 27, 2003).

"Research Methods and Ethics: Informed Consent and Conflicts of Interest" Invited Workshop, Center for Professional and Applied Ethics, The University of North Carolina at Charlotte, Charlotte, NC (Mar. 27, 2003).

"Inadvertent Germline Effects of Gene Transfer: Is It an Issue?" Invited Seminar, Johns Hopkins Bloomberg School of Public Health & The Phoebe R. Berman Bioethics Institute, Johns Hopkins University, Baltimore, MD (Mar. 3, 2003).

"Gene Transfer Research Consent Forms: What They Say" Invited Seminar, Greenwall Fellows Program, Johns Hopkins Bloomberg School of Public Health & The Phoebe R. Berman Bioethics Institute, Johns Hopkins University, Baltimore, MD (Mar. 3, 2003).

"Ethical Considerations in Gene Transfer Research: The IBC's Role," Invited Presentation, OBA Conference, The Future Face of IBCs, San Diego, CA (Feb. 22, 2003).

"What Research Consent Forms Say, And Why It Matters," Invited Lecture, Medical Humanities Hour, University of Maryland Medical Center, Baltimore, MD (Nov. 21, 2002).

"Advice and Consent: Ethics and Gene Transfer Research for Providers", Invited Presentation, Preconference Medical Symposium, National Hemophilia Foundation Annual Meeting, Lake Buena Vista, FL (October 31, 2002).

"What Consent Forms Say--And Why It Matters," Refereed Panel Presentation, ASBH Annual Meeting, Baltimore, MD (October 26, 2002).

"Clinical Trials and Genetic Disease: Policy Insights from Gene Transfer Research," Invited Presentation, Greenwood Genetic Center Faculty Retreat, Greenville, SC (Sept. 6, 2002)

"What Consent Forms Say (And Why It Matters)," Panel Presentation, Health Law Teachers 26th Annual Meeting, Indianapolis, IN (June 7, 2002).

"IRBs and Gene Transfer Research" and "Ethical Issues in Gene Transfer Research," Invited Presentations, Clinical Gene Transfer Review Course, American Society of Gene Therapy Annual Meeting, Boston, MA (June 4-5, 2002).

"Accident and Desire: Germline Interventions and Effects in Clinical Research,", Invited Presentation, Germ Line Interventions and Human Research Ethics Colloquium, Washington University, St. Louis, MO (April 5, 2002).

"Decisionmaking About Gene Transfer Research," Invited Plenary Panel Presentation, PRIM&R Annual Meeting, Boston, MA (December 4, 2001).

"The Line Between Clinical Innovation and Human Experimentation," Invited Presentation, Human Subjects Research Symposium, Seton Hall School of Law, Newark, NJ (November 9, 2001).

"Decisionmaking About Gene Transfer Research," Panel Presentation, Health Law Teachers 25th Annual Meeting, Boston, MA (June 2, 2001).

"Ethical Issues in Gene Transfer Research," Invited Presentation, Clinical Gene Transfer Training Course, American Society of Gene Therapy Annual Meeting, Seattle, WA (May 30, 2001).

"Relationships in Research," Invited Presentation, AAAS Short Course on Racial and Ethnic Minorities as Research Subjects, Tuskegee, AL (May 19, 2001).

"Ethical Issues in Gene Transfer Research," Invited Presentation, Human Genome Lecture Series, National Human Genome Research Institute, NIH, Bethesda, MD (January 18, 2001).

"Patients as Subjects," Refereed Panel Presentation, ASBH Annual Meeting, Salt Lake City, UT (October 29, 2000).

"The Portable DNR Order: Legal Implications and Implementation Issues," Invited Presentation, Piedmont Bioethics Network Annual Conference, High Point, NC (Sept. 25, 2000).

"Defining and Describing Benefit in Clinical Research," Invited Presentation, Western IRB 16th Annual Training Seminar, Seattle, WA (August 25, 2000).

"Risk-Benefit Assessment in Gene Transfer Research: Ethical and Policy Considerations," Invited Plenary Panel Presentation, Toxicology Forum 26th Annual Summer Meeting, Aspen, CO (June 14, 2000).

"Benefit in Clinical Trials," Panel Presentation, Health Law Teachers Annual Meeting, Cleveland, OH (June 9, 2000).

"Safety Issues from the Gene Transfer Experience," Invited Presentation, Working Conference on Institutional Review Boards and Data & Safety Monitoring Committees in the Monitoring of Clinical Trials, Duke Clinical Research Institute, Durham, NC (May 11, 2000).

"Defining and Describing Benefit Appropriately in Clinical Trials," Invited Plenary Panel Presentation, PRIM&R Annual Meeting, Boston, MA (December 6, 1999).

"Benefit in Research," Nijmegen Medical Ethics Colloquium, Department of Ethics, Philosophy, and History of Medicine and Department of Internal Medicine, University of Nijmegen, the Netherlands (November 15, 1999).

"A Reasonable Chance of Benefit in Clinical Research," Refereed Panel Presentation, ASBH Annual Meeting, Philadelphia, PA (October 29, 1999).

"Patients' Rights versus Research Needs," Plenary Presentation (with Daniel K. Nelson), NCHICA Annual Conference, Asheville, NC (September 20, 1999).

"Inadvertent Germline Effects of Gene Transfer Research: Ethical and Social Issues," Invited FDA Panel Presentation, Recombinant DNA Advisory Committee Meeting, NIH, Bethesda, MD (March 12, 1999).

Portable DNR Orders: The Moral and Legal Basis," Invited Presentation, North Carolina Hospital Association, Raleigh, NC (October 26, 1998).

"Points of Education, Policy, and Practice About End-of-Life Care and Treatment Decisions for Healthcare Providers and the Public in North Carolina," Invited Presentation, End of Life Decisions Forum, Raleigh, NC (October 23, 1998).

"Ethical Issues in Genetic Screening and Prenatal Diagnosis," American Cleft Palate- Craniofacial Association Preconference Symposium, Baltimore, MD (April 20, 1998).

"Beyond the IRB: Responsibilities to Research Participants and Populations," Invited Presentation, Keynote Remarks and Panel Discussion, UNC School of Public Health (March 25, 1998).

"Ethical Dilemmas in Cross-National Research" Workshop, INCLEN XV Global Meeting, Querétaro, Mexico (February 20, 1998).

"Emergency Research: Concerns about Implementing the Informed Consent Waiver," Invited Presentation, Human Subjects Workshop - Contemporary Issues in Human Subjects Research, Carolinas Medical Center, Charlotte, NC (September 23, 1997).

"Commentary on Genetic Enhancement," Invited Presentation, NIH Gene Therapy Policy Conference, Bethesda, MD (September 11, 1997).

"Ethics: End of Life Issues," Invited Presentation, Workshop, North Carolina Association for Home Care 25th Annual Convention, Raleigh, NC (April 25, 1997).

"Informed Consent and 'Gene Therapy' Research," AHCPR Seminar, Rockville, MD (April 18, 1997).

"Experimental Treatment: Oxymoron or Aspiration?," Invited Presentation, American Cancer Society Science Writers Seminar, Reston, VA (March 24, 1997).

"Normal Volunteers as Subjects in Gene Transfer Research: Commentary," Invited Presentation, Recombinant DNA Advisory Committee Meeting, Bethesda, MD (March 6, 1997).

"Research Ethics Workshop," INCLEN XIII Global Meeting, Victoria Falls, Zimbabwe (January 20-23, 1996).